Core Viewpoint - The controlling shareholder and actual controller of Haitai Xinguang, Mr. Zheng Anmin, plans to reduce his holdings by no more than 3.278 million shares, accounting for no more than 2.7345% of the company's total share capital [1] Summary by Sections - **Share Reduction Details** - The planned reduction includes a maximum of 918,000 shares through centralized bidding and 2.36 million shares through block trading [1] - The reduction period is set from 15 trading days after the announcement, specifically from November 14, 2025, to February 13, 2026 [1] - **Reason for Reduction** - The reason for the share reduction is stated as personal funding needs [1] - **Impact on Company** - This reduction will not lead to a change in the controlling shareholder or actual controller of the company [1] - It is also indicated that the reduction will not have a significant impact on the company's ongoing stable operations [1]

Core Viewpoint - The company, Qingdao Haitai Newlight Technology Co., Ltd., will hold a performance briefing for the third quarter of 2025 to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for October 28, 2025, from 15:00 to 16:30 [2][4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via audio live streaming and online interaction [2][4]. - Investors can submit questions from October 21 to October 27, 2025, before 16:00, through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants in the meeting will include the company's board members, general manager Zheng Yao, and financial director Wang Fanghua [4]. - Independent director Wang Ming will also be present during the briefing [4]. Group 3: Post-Meeting Access - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [5].

证券代码：688677 证券简称：海泰新光 公告编号：2025-058 青岛海泰新光科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心音频直播和网络互动 会议召开时间：2025 年 10 月 28 日（星期二）15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： （一）会议召开时间：2025 年 10 月 28 日（星期二）15:00-16:30 （二）会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心音频直播和网络互动 三、参加人员 董事、总经理：郑耀 投资者可于 2025 年 10 月 21 日（星期二）至 10 月 27 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investment@novelbea ...

Core Viewpoint - The company's medical endoscope equipment business is expected to be impacted by US-China tariffs, while the maintenance services and optical products business are performing well. Looking ahead to the second half of the year, strong demand from US clients is anticipated, with overseas shipment volumes expected to continue growing due to accelerated order deliveries. Revenue in Q3 2025 is projected to grow rapidly on a low year-on-year basis, with profit growth expected to outpace revenue growth. The collaboration with US clients is likely to deepen, with ongoing development of new endoscope types and next-generation systems, alongside rapid growth in maintenance services and steady progress in new projects like the gas insufflator, which will contribute to long-term growth and performance increments [1]. Financial Performance - In the first half of 2025, the company achieved operating revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 266 million yuan, 74 million yuan, and 72 million yuan, respectively, representing year-on-year growth of 20.50%, 5.52%, and 12.07%. Basic earnings per share were 0.62 yuan per share [2]. Business Segment Analysis - In the first half of 2025, the medical endoscope equipment revenue was 172 million yuan (+11.70%), accounting for 64.86% of total revenue, with growth pressured by US tariffs. Optical products revenue was 57 million yuan (+34.62%), making up 21.63% of total revenue, with medical optical products growing by 48% due to significant increases in diagnostic analysis and oral scanning products. Maintenance services revenue reached 35 million yuan (+60.58%), driven by the continuous increase in market share of the company's products. The maintenance business's gross margin was 84%, significantly higher than other segments, indicating potential positive contributions to overall gross margin [4]. Outlook for the Second Half - The company has effectively reduced tariff impact through proactive overseas capacity layout, with most products shipped to the US now being produced and delivered from the Thailand factory. Strong demand from US clients is expected to continue, with accelerated order deliveries likely to boost overseas shipment volumes. The collaboration with US clients is deepening, with the development of next-generation endoscope systems incorporating the company's optical defogging patent technology. The company is also exploring collaborations on gas insufflators and 3D endoscope systems, with the gas insufflator project progressing rapidly towards customer testing and subsequent FDA registration [5]. Profitability and Cash Flow - The company's gross margin for the first half of 2025 was 65.84% (+1.75 percentage points), showing slight growth. The sales expense ratio was 7.48% (+2.83 percentage points), reflecting increased spending on market expansion and marketing network improvement. The management expense ratio remained stable at 10.80% (-0.11 percentage points), while the R&D expense ratio improved to 12.51% (-1.47 percentage points) due to revenue growth. The operating cash flow net amount was 81 million yuan, up 25.87% year-on-year, driven by increased sales and improved cash collection efficiency [7][6]. Long-term Growth Potential - The company is a leading upstream manufacturer of fluorescent rigid endoscopes in China. In the short to medium term, strong demand from US clients and successful production transitions at the Thailand factory are expected to support steady growth in ODM business. The ongoing deepening of collaboration with US clients, alongside rapid growth in maintenance services and new projects, will lay a foundation for long-term growth and performance increments. The company's optical technology advantages and strong vertical integration capabilities position it well for future growth through the expansion of new clients and application areas [8].

Core Viewpoint - The company, Haitai New Light, has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector, particularly in optical technology applications [1][2]. Company Overview - Haitai New Light Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on June 11, 2003. The company went public on February 26, 2021, and specializes in the research, development, production, and sales of medical endoscope devices and optical products [7]. - The company's main business revenue composition includes: medical endoscope devices (64.86%), optical products (21.63%), maintenance services (13.09%), and leasing (0.42%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 266 million yuan, representing a year-on-year growth of 20.50%. The net profit attributable to the parent company was 74.44 million yuan, with a year-on-year increase of 5.52% [7]. - As of June 30, 2025, the company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title awarded to small and medium-sized enterprises in China that excel in niche markets and possess strong innovation capabilities [2]. - Haitai New Light has a vertical integration capability in the industry, covering core components, key equipment, and system integration, making it one of the few companies in China with such comprehensive capabilities [2]. International Revenue Impact - The company's overseas revenue accounted for 69.12% of total revenue in the 2024 annual report, benefiting from the depreciation of the Chinese yuan [3].

证券代码：688677 证券简称：海泰新光 公告编号：2025-057 | 回购方案首次披露日 | 2025/3/5 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 3 3 | 3 | 日~2026 | 年 | 日 2 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 138.7万股 | | | | | | 累计已回购股数占总股本比例 | 1.1570% | | | | | | 累计已回购金额 | 4,998.22万元 | | | | | | 实际回购价格区间 | 28.53元/股~40.92元/股 | | | | | 一、回购股份的基本情况 公司于 2025 年 3 月 3 日召开第四届董事会第三次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"），同意 公 ...

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge applications in the medical device industry, particularly in high-performance endoscopic instruments [2][7]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscopic instruments and optical products [7]. - The revenue composition of the company is as follows: medical endoscopic instruments 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. - As of June 30, 2025, the company reported a revenue of 266 million yuan, representing a year-on-year growth of 20.50%, and a net profit attributable to shareholders of 74.44 million yuan, up 5.52% year-on-year [7]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [2]. - The company has a vertical integration capability from core components to system integration, making it one of the few in the industry with such comprehensive capabilities [2]. Financial Performance - As of September 29, the company's market capitalization was 5.924 billion yuan, with a trading volume of 83.65 million yuan and a turnover rate of 1.43% [1]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 18.87% to 5,285, while the average circulating shares per person decreased by 16.39% to 22,682 shares [7][8]. - Major shareholders include various mutual funds, with specific holdings reported for several funds [8][9]. Technical Analysis - The average trading cost of the stock is 43.10 yuan, with the current stock price fluctuating between resistance at 51.00 yuan and support at 48.40 yuan, indicating potential for range trading [6]. International Revenue Impact - The company benefits from a significant overseas revenue share of 69.12%, which is positively impacted by the depreciation of the Chinese yuan [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady growth in performance, with significant overseas revenue growth [5] - The construction of overseas production capacity is progressing smoothly, with the Thailand factory becoming a key production site [6] - The company is expected to achieve revenue of 5.60 billion, 6.75 billion, and 8.17 billion from 2025 to 2027, with corresponding net profits of 1.88 billion, 2.32 billion, and 2.86 billion [7][8] Summary by Sections Financial Performance - In the first half of 2025, the company achieved revenue of 266 million (yoy +20.50%) and a net profit of 74 million (yoy +5.52%) [4] - For Q2 2025, the company reported revenue of 119 million (yoy +15.52%) and a net profit of 28 million (yoy -13.55%) [4] Revenue Breakdown - Medical endoscope revenue reached 207 million (yoy +17.72%), with significant growth in overseas sales [5] - Domestic revenue was 67 million (yoy +1.52%), while overseas revenue was 198 million (yoy +28.57%) [5] Production Capacity - The company has established endoscope and light source module production lines in Thailand, supporting exports to the U.S. and mitigating tariff impacts [6] - The company is collaborating with a major U.S. client on the next-generation endoscope system, expanding its product offerings [6] Future Projections - Revenue growth rates are projected at 26.5%, 20.5%, and 21.1% for 2025, 2026, and 2027 respectively [7] - The company anticipates a recovery in order placement rhythm following the completion of inventory adjustments by major clients [8]

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price but has strong fundamentals and growth potential in the medical device sector, particularly in endoscopic instruments and optical products [1][2]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscopic instruments and optical products [7]. - The revenue composition of the company includes 64.86% from medical endoscopic instruments, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. - As of June 30, 2025, the company reported a revenue of 266 million yuan, representing a year-on-year growth of 20.50%, and a net profit of 74.44 million yuan, with a growth of 5.52% [7]. Market Position and Recognition - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [2]. - The company has a vertical integration capability from core components to system integration, making it one of the few in the domestic market with such capabilities [2]. Financial Performance - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. - As of June 30, 2025, the number of shareholders increased by 18.87% to 5,285, while the average circulating shares per person decreased by 16.39% to 22,682 shares [7]. International Exposure - The company benefits from a significant overseas revenue share, which accounted for 69.12% of total revenue in the 2024 annual report, positively impacted by the depreciation of the Chinese yuan [3].

来源：新浪证券-红岸工作室 3、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入670.78万，占比0.06%，行业排名15/131，连续2日被主力资金增仓；所属行业主力净流 入8238.33万，连续2日被主力资金增仓。 区间今日近3日近5日近10日近20日主力净流入670.78万700.09万93.02万-761.28万220.42万 主力持仓 9月25日，海泰新光涨3.90%，成交额1.10亿元，换手率1.84%，总市值60.31亿元。 异动分析 医疗器械概念+专精特新+人民币贬值受益 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升 ...